Selective tissue targeting of synthetic nucleic acid drugs
Punit P. Seth, Michael Tanowitz, and C. Frank Bennett
Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
Address correspondence to: C. Frank Bennett, Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, California 92010, USA. Phone: 760.603.2336; Email: fbennett@ionisph.com.
Find articles by
Seth, P.
in:
JCI
|
PubMed
|
Google Scholar
|
Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
Address correspondence to: C. Frank Bennett, Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, California 92010, USA. Phone: 760.603.2336; Email: fbennett@ionisph.com.
Find articles by Tanowitz, M. in: JCI | PubMed | Google Scholar
Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
Address correspondence to: C. Frank Bennett, Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, California 92010, USA. Phone: 760.603.2336; Email: fbennett@ionisph.com.
Find articles by Bennett, C. in: JCI | PubMed | Google Scholar
First published January 28, 2019 - More info
Copyright © 2019, American Society for Clinical Investigation
Antisense oligonucleotides (ASOs) are chemically synthesized nucleic acid analogs designed to bind to RNA by Watson-Crick base pairing. Following binding to the targeted RNA, the ASO perturbs RNA function by promoting selective degradation of the targeted RNA, altering RNA intermediary metabolism, or disrupting function of the RNA. Most antisense drugs are chemically modified to enhance their pharmacological properties and for passive targeting of the tissues of therapeutic interest. Recent advances in selective tissue targeting have resulted in a newer generation of ASO drugs that are more potent and better tolerated than previous generations, spawning renewed interest in identifying selective ligands that enhance targeted delivery of ASOs to tissues.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)